Clinical trial of conbercept injection in the treatment of neovascular eye disease
10.13699/j.cnki.1001-6821.2019.07.008
- VernacularTitle:康柏西普注射液治疗新生血管性眼病的临床研究
- Author:
Le-Le CUI
1
;
Rong LIU
;
Yun-Song WANG
;
Chang-Ming LIU
;
Li-Zhen JIN
Author Information
1. 唐山市工人医院 眼科
- Keywords:
conbercept injection;
neovascular eye disease;
safety evaluation
- From:
The Chinese Journal of Clinical Pharmacology
2019;35(7):627-629
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of conbercept injection in the treatment of neovascular eye disease. Methods Thirty patients with neovascular eye disease were selected as research objects, which were given conbercept 0. 2 m L, injected into the glass cavity. Before operation and 3 months after operation, the changes of vision, central macular thickness (CMT) , serum levels of vascular endothelial growth factor (VEGF) , retinal blood flow and adverse drug reactions were observed. Results 3 months after operation and before operation, the vision were (0. 49 ± 0. 05) and (0. 68 ± 0. 12) logMAR, CMT were (196. 48 ± 11. 60) and (250. 23 ± 16. 45) μm, VEGF were (96. 85 ± 14. 61) and (152. 04 ± 13. 75) ng·L-1, peak systolic velocity were (10. 90 ± 1. 87) and (8. 38 ± 1. 46) cm·s-1, end-diastolic velocity were (3. 21 ± 0. 37) and (2. 06 ± 0. 29) cm·s-1, resistance indexes were (0. 57 ± 0. 09) and (0. 70 ± 0. 11) , maximum systolic flow velocity were (7. 27 ± 0. 82) and (8. 55 ± 1. 09) cm · s-1, minimum diastolic flow velocity were (4. 04 ± 0. 81) and (5. 08 ± 0. 99) cm·s-1, the differences were statistically significant (all P < 0. 05) . There were no adverse drug reactions observed in all patients during the treatment.Conclusion Conbercept injection has a safety in the treatment of neovascular eye disease, which can significantly decrease the patients 'serum levels of VEGF and improve the vision.
